Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Amyloidosis Channel is supported with funding from Prothena (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

VJVirtual | Complete hematological response prior to renal transplant in AL amyloidosis

Ashutosh Wechalekar • 1 Jun 2020
Amyloidosis Rare Diseases Antibodies Daratumumab

Ashutosh Wechalekar, MBBS, FRCP, FRCPath, University College London Hospitals NHS Trust, London, UK, discusses the importance of achieving a complete hematological response prior to renal transplants in amyloid light-chain (AL) amyloidosis in order to improve patients outcomes. This interview was recorded via an online conference call with the Video Journal of Hematological Oncology (VJHemOnc).

More from Ashutosh Wechalekar

Advances in the treatment and diagnosis of amyloidosis: what does the future hold?
1:36
Advances in the treatment and diagnosis of amyloidosis: what does the future hold?
Ashutosh Wechalekar • 13 Jun 2025
Treatment strategies for patients with R/R amyloidosis: targeting BCL2 or BCMA
1:34
Treatment strategies for patients with R/R amyloidosis: targeting BCL2 or BCMA
Ashutosh Wechalekar • 13 Jun 2025
Hidden light chain amyloidosis in patients with multiple myeloma
1:45
Hidden light chain amyloidosis in patients with multiple myeloma
Ashutosh Wechalekar • 13 Jun 2025
Results of the Phase III AFFIRM-AL trial of birtamimab in AL amyloidosis
1:12
Results of the Phase III AFFIRM-AL trial of birtamimab in AL amyloidosis
Ashutosh Wechalekar • 14 Jun 2025

Related Videos

Federated learning to train generative AI models for diagnosis & prognosis of hematological diseases
2:08
Federated learning to train generative AI models for diagnosis & prognosis of hematological diseases
Ashutosh Wechalekar • 7 Dec 2025
Initial results from the NEXICART-2 trial of BCMA-directed CAR-T (NXC-201) in R/R AL amyloidosis
2:25
Initial results from the NEXICART-2 trial of BCMA-directed CAR-T (NXC-201) in R/R AL amyloidosis
Ashutosh Wechalekar • 5 Dec 2025
Investigating novel therapeutic approaches for T-cell lymphoma
1:01
Investigating novel therapeutic approaches for T-cell lymphoma
Ashutosh Wechalekar • 8 Dec 2025
Phase II REVIVE trial: teclistamab plus daratumumab for high-risk smoldering multiple myeloma
3:45
Phase II REVIVE trial: teclistamab plus daratumumab for high-risk smoldering multiple myeloma
Ashutosh Wechalekar • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals